Tag: trophoblast cell-surface antigen 2
Results of Preclinical Data for GQ1010 Confirm Potential for Best-In-Class TROP2-Targeted...
The trophoblast cell surface antigen 2 (TROP2), a transmembrane glycoprotein that plays a role in cell self-renewal, proliferation, and transformation and survival, is overexpressed in many forms of cancers independent of baseline levels of TROP2 expression.
Combinations with Datopotamab Deruxtecan Show Promising Clinical activity in Treatment of...
Initial results from the TROPION-Lung02 Phase Ib trial demonstrated that that datopotamab deruxtecan (Dato-DXd), a specifically designed TROP2-directed DXd antibody drug conjugate (ADC) being...
Kelun-Biotech Signs Oncology Research Collaboration Agreement with Merck/MSD
Chinese clinical-stage biotech company Kelun-Biotech*, a subsidiary of Sichuan Kelun Pharmaceutical, has signed an exclusive license agreement with Merck & Co/MSD to develop an...
Daiichi Sankyo: Realigning for Agility
Daiichi Sankyo first approached me in 2015 with a potential opportunity in global oncology development, and I listened carefully as they explained how they...
Phase I Study of DS-1062 in Patients with Advanced Non-Small Cell...
The first patient has been dosed in a phase I study assessing the safety and tolerability of DS-1062, an investigational trophoblast cell-surface antigen 2...
